Johnson & Johnson Cost of Goods Sold 2010-2025 | JNJ
Johnson & Johnson annual/quarterly cost of goods sold history and growth rate from 2010 to 2025. Cost of goods sold can be defined as the difference between beginning and ending inventories for tangible products resulting in an expense that reflects production and sales costs.
- Johnson & Johnson cost of goods sold for the quarter ending March 31, 2025 was $7.357B, a 12.99% increase year-over-year.
- Johnson & Johnson cost of goods sold for the twelve months ending March 31, 2025 was $28.317B, a 7.35% increase year-over-year.
- Johnson & Johnson annual cost of goods sold for 2024 was $27.471B, a 3.46% increase from 2023.
- Johnson & Johnson annual cost of goods sold for 2023 was $26.553B, a 7.96% increase from 2022.
- Johnson & Johnson annual cost of goods sold for 2022 was $24.596B, a 5.1% increase from 2021.
Johnson & Johnson Annual Cost of Goods Sold
(Millions of US $) |
| 2024 |
$27,471 |
| 2023 |
$26,553 |
| 2022 |
$24,596 |
| 2021 |
$23,402 |
| 2020 |
$28,427 |
| 2019 |
$27,556 |
| 2018 |
$27,091 |
| 2017 |
$25,439 |
| 2016 |
$21,789 |
| 2015 |
$21,536 |
| 2014 |
$22,746 |
| 2013 |
$22,342 |
| 2012 |
$21,658 |
| 2011 |
$20,360 |
| 2010 |
$18,792 |
| 2009 |
$18,447 |
Johnson & Johnson Quarterly Cost of Goods Sold
(Millions of US $) |
| 2025-03-31 |
$7,357 |
| 2024-12-31 |
$7,128 |
| 2024-09-30 |
$6,963 |
| 2024-06-30 |
$6,869 |
| 2024-03-31 |
$6,511 |
| 2023-12-31 |
$6,798 |
| 2023-09-30 |
$6,606 |
| 2023-06-30 |
$6,462 |
| 2023-03-31 |
$6,687 |
| 2022-12-31 |
$2,907 |
| 2022-09-30 |
$6,172 |
| 2022-06-30 |
$7,919 |
| 2022-03-31 |
$7,598 |
| 2021-12-31 |
$1,502 |
| 2021-09-30 |
$7,250 |
| 2021-06-30 |
$7,587 |
| 2021-03-31 |
$7,063 |
| 2020-12-31 |
$7,814 |
| 2020-09-30 |
$6,972 |
| 2020-06-30 |
$6,579 |
| 2020-03-31 |
$7,062 |
| 2019-12-31 |
$7,134 |
| 2019-09-30 |
$6,867 |
| 2019-06-30 |
$6,940 |
| 2019-03-31 |
$6,615 |
| 2018-12-31 |
$6,961 |
| 2018-09-30 |
$6,589 |
| 2018-06-30 |
$6,927 |
| 2018-03-31 |
$6,614 |
| 2017-12-31 |
$7,259 |
| 2017-09-30 |
$6,925 |
| 2017-06-30 |
$5,846 |
| 2017-03-31 |
$5,409 |
| 2016-12-31 |
$5,638 |
| 2016-09-30 |
$5,486 |
| 2016-06-30 |
$5,336 |
| 2016-03-31 |
$5,329 |
| 2015-12-31 |
$5,673 |
| 2015-09-30 |
$5,224 |
| 2015-06-30 |
$5,357 |
| 2015-03-31 |
$5,282 |
| 2014-12-31 |
$5,853 |
| 2014-09-30 |
$5,399 |
| 2014-06-30 |
$6,039 |
| 2014-03-31 |
$5,455 |
| 2013-12-31 |
$5,955 |
| 2013-09-30 |
$5,344 |
| 2013-06-30 |
$5,489 |
| 2013-03-31 |
$5,554 |
| 2012-12-31 |
$6,003 |
| 2012-09-30 |
$5,597 |
| 2012-06-30 |
$5,143 |
| 2012-03-31 |
$4,915 |
| 2011-12-31 |
$5,338 |
| 2011-09-30 |
$5,072 |
| 2011-06-30 |
$5,172 |
| 2011-03-31 |
$4,778 |
| 2010-12-31 |
$5,040 |
| 2010-09-30 |
$4,594 |
| 2010-06-30 |
$4,630 |
| 2010-03-31 |
$4,528 |
| 2009-12-31 |
$5,312 |
| 2009-09-30 |
$4,434 |
| 2009-06-30 |
$4,450 |
| 2009-03-31 |
$4,251 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharma |
$371.642B |
$88.821B |
|
Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among pharma companies. J&J's worldwide business is divided into three segments: Pharmaceutical, Medical Devices and Consumer. The company has several drugs covering a broad range of areas such as neuroscience, cardiovascular & metabolism, immunology, oncology, pulmonary hypertension and infectious diseases and vaccines. The Medical Devices Segment offers products in the orthopedics, surgery, interventional solutions and vision markets. The Consumer Segment segment includes a broad range of products covering the areas of baby care, beauty/skin health, oral care, wound care and womens' health care, as well as over-the-counter (OTC) pharmaceutical products.
|
